TYK Medicines Inc
02410
Company Profile
Business description
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
Contact
No.277 Longlan Road
8th Floor, Building T2
China Eastern Binjiang Center
Xuhui District
Shanghai
CHNT: +86 2161676766
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
173
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,101.59 | 15.83 | -0.20% |
| DAX 40 | 24,663.19 | 74.05 | -0.30% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,392.99 | 39.35 | -0.38% |
| HKSE | 25,394.64 | 256.48 | -1.00% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |